摘要
目的判断骨转移瘤患者经过放射性核素89SrCl2治疗后免疫学指标CD4+,CD8+及CD4+/CD8+的变化及该指标对治疗效果的监控作用。方法选择经临床确诊的应用89SrCl2治疗的患者及正常对照组各24例。用流式细胞仪分别测定各患者治疗前、后及正常对照组CD4+,CD8+及CD4+/CD8+值。每例患者均于治疗后第2,4和6个月行全身骨显像,记录骨转移病灶数及计算平均值。结果正常对照组CD4+,CD4+/CD8+值高于骨转移瘤患者,而CD8+值低于骨转移瘤患者(P<0.05)。89SrCl2治疗后病灶数随CD4+增加、CD8+降低、CD4+/CD8+增加而相应减少。第4个月89SrCl2作用达峰值,各指标也达到极限值。结论CD4+,CD8+,CD4+/CD8+可以灵敏反映89SrCl2治疗效果,客观反映骨转移瘤病灶的变化。
Objective: To judge the therapeutic effects of bone metastases by the percents of CD4+, CD8+, CD4+/CD8+ before and after the treatment of 89SrCl2 in the patients with bone metastases. Methods: 24 patients who were diagnosed by clinic were treated with 89SrCl2. The CD4+, CD8+ and CD4+/CD8+ were detected by flow cytometry before and after 89SrCl2 treatment, as well in 24 controls. At the 2nd, 4th and 6th month after the administration, the bone scan with 99mTc-MDP was performed for all the patients and the quantities of bone metastases lesions were recorded. Result: The percents of CD4+ and CD4+/CD8+ in the controls group were higher than those in the patients with bone metastases, and the CD8+ levels were lower (P<0.05). After the treatment of 89SrCl2, the CD4+ and CD4+/CD8+ levels increased and the CD8+ level, the lesions decreased. These changes were the most obvious at the 4th month after the therapy. Conclusion: The CD4+, CD8+ and CD4+/CD8+ levels can sensitively reflect the therapeutic effects of 89SrCl2 and accurately estimate the conditions of bone metastases.
出处
《中国现代医学杂志》
CAS
CSCD
2004年第16期13-15,20,共4页
China Journal of Modern Medicine
